UBS Group
BNTX icon

UBS Group’s BioNTech BNTX Stock Holding History

UBS Group’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4M Buy
262,361
+21,823
+9% +$2.05M ﹤0.01% 2473
2026
Q1 		$21.4M Sell
240,538
-1,035
-0.4% -$106K ﹤0.01% 2519
2025
Q4 		$23M Sell
241,573
-365,867
-60% -$36.9M ﹤0.01% 2457
2025
Q3 		$59.9M Buy
607,440
+349,152
+135% +$37.3M 0.01% 1442
2025
Q2 		$27.5M Sell
258,288
-235,643
-48% -$23.8M ﹤0.01% 2052
2025
Q1 		$45M Sell
493,931
-35,122
-7% -$3.93M 0.01% 1574
2024
Q4 		$60.3M Buy
529,053
+406,072
+330% +$46.3M 0.01% 1300
2024
Q3 		$14.6M Sell
122,981
-42,563
-26% -$3.91M ﹤0.01% 2070
2024
Q2 		$13.3M Buy
165,544
+73,416
+80% +$6.71M ﹤0.01% 2004
2024
Q1 		$8.5M Sell
92,128
-21,650
-19% -$2.08M ﹤0.01% 2411
2023
Q4 		$12M Sell
113,778
-12,264
-10% -$1.24M ﹤0.01% 1946
2023
Q3 		$13.7M Buy
126,042
+23,073
+22% +$2.55M ﹤0.01% 1747
2023
Q2 		$11.1M Buy
102,969
+15,345
+18% +$1.73M ﹤0.01% 1891
2023
Q1 		$10.9M Sell
87,624
-39,068
-31% -$5.36M ﹤0.01% 1828
2022
Q4 		$19M Sell
126,692
-14,557
-10% -$2.24M 0.01% 1451
2022
Q3 		$19.1M Sell
141,249
-35,224
-20% -$5.38M 0.01% 1309
2022
Q2 		$26.3M Buy
176,473
+5,439
+3% +$831K 0.01% 1141
2022
Q1 		$29.2M Sell
171,034
-163,839
-49% -$27.5M 0.01% 1169
2021
Q4 		$86.3M Sell
334,873
-14,758
-4% -$4.04M 0.02% 666
2021
Q3 		$95.4M Buy
349,631
+43,057
+14% +$13.7M 0.03% 548
2021
Q2 		$68.6M Buy
306,574
+22,845
+8% +$4.31M 0.02% 679
2021
Q1 		$31M Buy
283,729
+230,057
+429% +$24.4M 0.01% 1142
2020
Q4 		$4.38M Sell
53,672
-59,879
-53% -$5.88M ﹤0.01% 2594
2020
Q3 		$7.86M Buy
113,551
+60,713
+115% +$4.36M ﹤0.01% 1824
2020
Q2 		$3.53M Buy
52,838
+47,948
+981% +$2.39M ﹤0.01% 2343
2020
Q1 		$286K Buy
4,890
+3,840
+366% +$149K ﹤0.01% 4432
2019
Q4 		$36K Buy
+1,050
New +$23.5K ﹤0.01% 6537

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

UBS Group's BNTX Position: Q2 2026 in Review

UBS Group increased its BioNTech (BNTX) stake by 9.1% in Q2 2026, buying an estimated $2.05M and bringing the position to 262,361 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2473.

UBS Group first reported a position in BNTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $95.4M in Q3 2021. 281 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • UBS Group held 262,361 shares of BioNTech worth $24.4M as of Q2 2026.
  • UBS Group bought 21,823 BioNTech shares in Q2 2026, an estimated $2.05M.
  • BioNTech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2473 holding.
  • UBS Group first reported a position in BioNTech in Q4 2019 and has held it in 27 quarters since.
  • UBS Group's BioNTech position peaked at $95.4M in Q3 2021.
  • 281 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.